Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PCSAthis companyProcessa Pharmaceuticals, Inc.	$1.90	-0.28×	0.68×	0×	0.13×	88.7%	0.0%	0.0%	0.0%	-243.2%	-250.8%	-301.9%	0×	0.41×	0×	2.54×	0.0%	1	-92.98	2	B-
ALLRAllarity Therapeutics, Inc.	$0.98	-1.38×	1.58×	48.53×	-0.2×	20.0%	100.0%	-3939.1%	-3509.7%	-114.3%	-112.3%	-95.5%	0.14×	1.2×	-68.14×	2.13×	0.0%	1	-6.62	1	C-
CRISCuris, Inc.	$0.75	-1.7×	2.38×	1.38×	-1.83×	-1429.1%	99.5%	-348.4%	-80.3%	-138.8%	-464.7%	-209.4%	0.3×	0.66×	-15.06×	0.49×	0.0%	0	-98.45	1	C-
CTXRCitius Pharmaceuticals, Inc.	$0.55	-0.37×	0.2×	0×	-0.3×	64.2%	0.0%	0.0%	0.0%	-55.4%	-44.2%	-193.5%	0.03×	0.06×	-143.87×	0.62×	0.0%	3	-4.03	2	B-
MBRXMoleculin Biotech, Inc.	$8.52	-0.12×	0.26×	0×	0.14×	983.9%	0.0%	0.0%	0.0%	-223.6%	-162.9%	-579.8%	0.02×	0.25×	0×	1.41×	0.0%	1	-19.26	3	B-
PALIPalisade Bio, Inc.	$1.20	-7.83×	1.01×	0×	0.15×	113.1%	0.0%	0.0%	0.0%	-13.0%	-13.9%	-8.3%	0×	7.95×	-1,805.6×	28.95×	0.0%	4	19.43	2	C
Peer median	—	-1.38×	1.01×	0×	-0.2×	64.2%	0.0%	0.0%	0.0%	-114.3%	-112.3%	-193.5%	0.03×	0.66×	-68.14×	1.41×	0.0%	1	-6.62	2	—